does ghk cu affect growth hormone levels 7% GHK-CU ACCELERANT Peptide Therapy for Inflammation: A

There are no jitters, no appetite suppression through hormonal signaling, and no dependency concerns that come with stimulant-based approaches

Start: 5 mg daily for Weeks 12 to assess individual tolerance

In this study, we designed a peptide inhibitor based on the p53 transactivation domain (TAD) sequence and investigated its binding interface at the atomic level using NMR spectroscopy

_ Let's talk about your project

Disclosure of interest: None Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P682 - ESOC25-1141 RISK OF SYMPTOMATIC INTRACRANIAL HEMORRHAGE IN ENDOVASCULAR STROKE TREATMENT: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Joo Andr Sousa 1 , Sara Bernardo-Castro 2 , Joao Nuno Ramos 3 , Helena Donato 4 , Joo Sargento Freitas 1 1 Stroke Unit, Unidade Local de Sade de Coimbra, Portugal, Coimbra, Portugal, 2 IISPV Pere Virgili Health Research Institute, Tarragona, Spain, 3 Diagnostic Neuroradiology Unit, Imaging Department, Unidade Local de Sade Gaia e Espinho, Vila Nova de Gaia, Portugal, Vila Nova de Gaia, Portugal, 4 Documentation and Scientific Information Service, Hospitais da Universidade de Coimbra, Unidade Local de Sade de Coimbra, Portugal, Coimbra, Portugal Background and Aims: Symptomatic intracranial hemorrhage (sICH) is a key safety outcome in endovascular therapy (EVT) for acute ischemic stroke (AIS)